Compare Organon Pharma Indonesia Tbk. (SCPI) vs Saraswanti Indoland Development Tbk. (SWID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Saraswanti Indoland Development Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Saraswanti Indoland Development Tbk. trades at Rp117 (market cap 635.43B, 2.92M 24h volume). The key difference: Saraswanti Indoland Development Tbk. is far larger — about 6.1× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SWID | |
|---|---|---|
Market Cap | 104.4B | 635.43B |
Volume | — | 2.92M |
Lot | — | 29.25K |
Turnover | — | 343.27M |
Average Price | — | 117.38 |
Value | — | 343.27M |
Indicative Equilibrium Price | — | 117 |
Indicative Equilibrium Volume | — | 121 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Saraswanti Indoland Development Tbk.
PT Saraswanti Indoland Development Tbk ( The Company) was established on August 2, 2010 based on the Deed of Notary Ismaryani, SH, MKn. Number : 01. The deed of establishment of the Company was approved by the Minister of Law and Human Rights of the Republic of Indonesia number: AHU41610.AH.01.01.Tahun 2010. The Company started its commercial operations in 2011.
Read more on SWID →
